Bortezomib (PS-341): Advancing Proteasome Inhibitor Resea...

2025-09-23

Explore how Bortezomib (PS-341), a reversible proteasome inhibitor, facilitates research into proteasome-regulated cellular processes, programmed cell death, and novel ties to mitochondrial proteostasis in cancer and metabolic regulation.

Bortezomib (PS-341) as a Versatile Tool for Dissecting Pr...

2025-09-22

This article evaluates Bortezomib (PS-341), a reversible proteasome inhibitor, as a research tool for probing proteasome-regulated cellular processes, with a special focus on its application in elucidating the interplay between proteasome signaling and pyrimidine salvage pathways in cancer biology.

Vardenafil HCl Trihydrate: Advancing Proteoform-Specific ...

2025-09-19

Explore the unique utility of Vardenafil HCl Trihydrate as a potent and selective phosphodiesterase type 5 inhibitor in cutting-edge proteoform-specific research. This article highlights its role in dissecting cGMP pathway modulation and off-target effects in native signaling environments.

CP-809101 hydrochloride

2025-09-19

Bortezomib (PS-341): Mechanistic Insights into Reversible...

2025-09-18

Explore the molecular mechanisms by which Bortezomib (PS-341), a potent reversible proteasome inhibitor, orchestrates apoptosis in cancer cells. This article discusses recent findings on proteasome-regulated cellular processes, highlighting the intersection of proteasome inhibition and emerging cell death pathways in oncology research.

Ophiobolin B

2025-09-18

NHS-LC-LC-Biotin

2025-09-17

WEHI-539

2025-09-16

1A-116

2025-09-13

Anti-PTPRCCD45 Antibody (Apamistamab)

2025-09-13

Anti-CXCL11 Rabbit Monoclonal Antibody

2025-09-12

16-Ketoestradiol

2025-09-12

Dimaprit dihydrochloride

2025-09-11

H-Ser-His-OH

2025-09-10

Propargyl-PEG2-acid

2025-09-10